Fortrea Inc. (FTRE)
17.64
-0.67 (-3.66%)
At close: Jan 14, 2025, 3:59 PM
17.76
0.65%
After-hours Jan 14, 2025, 05:32 PM EST
undefined% (undefined)
| Bid | 7.1 |
| Market Cap | 1.58B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.46 |
| PE Ratio (ttm) | -7.17 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 20.09 |
| Volume | 821,014 |
| Avg. Volume (20D) | 1,226,831 |
| Open | 18.24 |
| Previous Close | 18.31 |
| Day's Range | 17.00 - 18.50 |
| 52-Week Range | 16.53 - 41.02 |
| Beta | undefined |
About FTRE
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2023
Employees 15,500
Stock Exchange NASDAQ
Ticker Symbol FTRE
Website https://www.fortrea.com
Analyst Forecast
According to 11 analyst ratings, the average rating for FTRE stock is "Hold." The 12-month stock price forecast is $23, which is an increase of 30.35% from the latest price.
Buy 0.00%
Hold 90.91%
Sell 9.09%
Next Earnings Release
Fortrea Inc. is scheduled to release its earnings on Mar 10, 2025,
before market opens.
Analysts project revenue of $703.90M, reflecting a -9.22% YoY shrinking and earnings per share of 0.37, making a 94.74% increase YoY.
Analysts project revenue of $703.90M, reflecting a -9.22% YoY shrinking and earnings per share of 0.37, making a 94.74% increase YoY.
1 month ago ·
Source
-8.06%
Fortrea shares are trading lower after Baird downg...
Unlock content with
Pro Subscription
2 months ago ·
Source
+30.19%
Fortrea shares are trading higher after the company issued FY24 revenue guidance above estimates.
